Biocon Biologics’ receives FDA approval for Biosimilar Aflibercept for Yesafili
The approval of YESAFILI marks Biocon Biologics’ expansion into the ophthalmology therapeutic area in the United States
The approval of YESAFILI marks Biocon Biologics’ expansion into the ophthalmology therapeutic area in the United States
The funds raised from the Whitathon run are utilized to treat underprivileged children suffering from Retinoblastoma
95.7% of patients responded to Breyanzi in the TRANSCEND FL trial
The award recognizes powerful science–industry collaborations for social good
At the recommended Phase 3 dose of 200 mg vepdegestrant in combination with palbociclib, patients achieved a median progression-free survival of 13.9 months
35,000 doctors from across India pledged their support for the initiative to raise awareness about cardiovascular diseases
EBITDA for the quarter stood at Rs 964 crore, representing an EBITDA margin of 24%
Pivotal OASIS 1 and 2 Phase III studies of investigational compound elinzanetant achieved a statistically significant reduction in frequency and severity of vasomotor symptoms
Cresset’s new India site will support the growing demands of Cresset’s APAC customer base
Subscribe To Our Newsletter & Stay Updated